OncorMed offers genetic testing for inherited cancers:
This article was originally published in Clinica
Executive Summary
OncorMed has launched a test for mutations in the recently discovered BRCA2 breast and ovarian cancer gene. The company which is based in Gaithersburg, Maryland, is providing the new service in combination with its existing BRCA1 test. Approximately 185,000 patients will be diagnosed with breast cancer this year in the US. Between 5 and 10% of breast cancer is hereditary, with BRCA1 mutations accounting for about 45% and BRCA2 mutations accounting for about 35% of these cases.